Trial
NCT01512199
Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Daiichi Sankyo
Collaborators
—
Condition
Metastatic Breast Cancer
Intervention
U3-1287
Why stopped
Improved, different standard of care caused business decision to terminate
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-10-18